In-depth analysis of the tear fluid glycoproteome reveals diverse lacritin glycosylation and spliceoforms
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Vincent Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Tears, Glycoproteins, Eye Proteins, Proteome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Cancer Research Institute, Oslo universitetssykehus HF.
Abstract (Originalsprache)
Tear fluid comprises a diverse group of extracellular glycoproteins which are critical for ocular homeostasis. Within the tear fluid glycoproteome, lacritin is highly expressed and plays a key role in immune response, tear secretion, and antimicrobial activity. Importantly, glycosylation constitutes over 50% of lacritin's molecular weight. However, despite this fact, nothing is known about the specific glycan structures on lacritin and how they influence its protein folding, function, or downstream biological processes. Similarly, it remains completely unknown whether alterations to lacritin glycans are correlated with ocular pathologies. To address this gap in knowledge, we harnessed mass spectrometry to conduct the first O-glycoproteomic study of tear fluid. Here, we report unprecedented coverage of lacritin glycosylation, detailing 19 O-glycosites bearing a myriad of glycan structures. Further, we leveraged AlphaFold 3.0 and GlycoShape to visualize the impact of these glycans on its structure, demonstrating that O-glycosylation renders the protein backbone rigid and extended. Surprisingly, we also detected protein-level evidence of two lacritin spliceoforms, representing the first observation of these isoforms by mass spectrometry. Simultaneously, we describe the most comprehensive characterization of the tear fluid glycoproteome to date, elucidating the glycosylation profile of immunoglobulin A, lactoferrin, and other glycoproteins with demonstrated clinical relevance as diagnostic biomarkers. Overall, this study lays the critical groundwork for future biochemical investigation of tear fluid glycoproteins and their application as diagnostic or therapeutic tools for ocular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Yale University, New Haven, Connecticut, USA.
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
- Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University Oslo Metropolitan University, Oslo, Norway.
- Department of Chemistry, Yale University, New Haven, Connecticut, USA. Electronic address: stacy.malaker@yale.edu.
Förderung
- NIGMS NIH HHS
- Cancer Research Institute
- Oslo universitetssykehus HF
- National Institute of General Medical Sciences
- National Science Foundation
Zitieren
APA
Chang, V., Mahoney, K. E., Lian, I., Chen, R., Chung, N., Utheim, T. P., Karlsson, N. G., & Malaker, S. A. (2025). In-depth analysis of the tear fluid glycoproteome reveals diverse lacritin glycosylation and spliceoforms. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110580
Vancouver
Chang V, Mahoney KE, Lian I, Chen R, Chung N, Utheim TP, et al. In-depth analysis of the tear fluid glycoproteome reveals diverse lacritin glycosylation and spliceoforms. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110580
BibTeX
@article{Chang2025,
author = {Chang, Vincent and Mahoney, Keira E and Lian, Isaac and Chen, Ryan and Chung, Nara and Utheim, Tor Paaske and Karlsson, Niclas G and Malaker, Stacy A},
title = {In-depth analysis of the tear fluid glycoproteome reveals diverse lacritin glycosylation and spliceoforms},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110580}
}
EUVIMED